Skip to content
Breathing, swallowing or vision problems: call the emergency services (15 or 112 in France).

Medical information platform

SOS Botox: medical information on botulinum toxin

SOS Botox explains botulinum toxin using official product information and scientific publications: why a facial area is treated, what the short-acting toxin changes, how long the effect takes to appear and to wear off, and what to do if the result is not what you expected. Every page is reviewed by a doctor.

SOS Botox is a medical information website about botulinum toxin, the medicine injected to soften certain wrinkles by temporarily relaxing a muscle. It is written for people with questions before a first injection, for those hesitating between two products, and for those worried about an unexpected result. The site sells nothing and makes no offers: it explains, it cites its sources, and it always refers you back to a conversation with your doctor, the only person who can assess your situation.

Start with the area that concerns you

The forehead is not treated like the jaw, nor frown lines like the neck. For each of the eleven areas of the face and neck, a page explains which muscle is involved, when the toxin is used, which toxin is approved for that area in France and which risks are described. Some areas correspond to an official indication, others do not: we say so clearly.

Interactive atlas

Why and how, area by area

Tap an area of the face to find out why it is treated, which toxin is approved for it in France and what to know before talking to your doctor.

Tap an area of the face

Front-view illustration of a face, from the forehead to the neck, with the atlas areas outlined

Choose an area

Understand before you decide

How does the toxin act on the muscle? Why does its effect take a few days to appear, and then fade? What are the contraindications, and what should you mention before an injection? The answers are gathered in our guide to what botulinum toxin is and how it is used, built on the summaries of product characteristics published by the health authorities.

A new generation of toxin: you now have a choice

Since July 2026, a short-acting botulinum toxin of a different type (serotype E) has been approved in the European Union for frown lines in adults, and for that area only2,3. As of 9 October 2026, it is also approved in Canada (since 22 June 2026)6. Its profile differs from that of type A toxins, which have been used for many years: its first effects appear from 8 hours and the effect usually lasts 2–3 weeks2, whereas with a type A toxin the first effects usually appear within 2–3 days1 and the effect usually lasts 3–4 months, up to 6 months depending on the product1,4,5.

Neither is better than the other: one works faster and for a shorter time, the other more slowly and for longer. The long-acting toxin remains the right choice in particular for a lasting effect and for the areas where it alone is approved. What is known today, and what is still unknown, is set out in our section on the new botulinum toxin.

Two families of toxins, two different profiles: one works faster and for a shorter time, the other more slowly and for longer. Neither is better than the other. The short-acting toxin gives you a choice, to be made with your doctor.

Comparison of the two families of botulinum toxins
CriterionLong-acting botulinum toxinType AShort-acting botulinum toxinSerotype E
First effects1,2,3,4Usually 2–3 days (up to one week)From 8 hours
Peak effect5,1,2,4Between week 2 and week 4Around day 7
Usual duration3,6,7,4Usually 3–4 months, up to 6 months depending on the product2–3 weeks
Approved aesthetic areas (France)3,2,8,4Frown lines; depending on the product, crow’s feet and forehead linesFrown lines only
Track record8,4Over 20 years of aesthetic use in France (first aesthetic approval: 2003)Approved in the European Union since July 2026
Treatment rhythm1,2,4Sessions at least 3 months apartOccasional use (as stated in the label)

No trial directly compares the two families of toxins: this table describes the data from their respective labels; it does not rank them.9

If the result is not what you expected

An eyebrow that rises too high, an eyelid that droops, a less symmetrical smile, or no effect at all: these situations are worrying, but most are temporary and disappear as the effect of the product wears off. Our SOS guide describes them area by area, with the same questions for each: why, for how long, is it reversible, what can be done and when to see a doctor. Difficulty swallowing, speaking or breathing, or a problem with your vision, on the other hand, means calling emergency services without waiting (15 or 112 in France, or your local emergency number).

How this site is written

Every piece of medical information refers to a verifiable source: official product information, reports from health agencies, peer-reviewed scientific publications. The texts are drafted with the help of an artificial intelligence tool, then reviewed and approved by a doctor before publication; the date of the latest review appears on every page. No brand name of any medicine is mentioned, and no page replaces a consultation.

An unexpected result after an injection?

Most problems are temporary, but some signs mean you should see a doctor quickly. Our guide helps you take stock.

Open the SOS guide

Sources

  1. 1.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 66865211) (opens in a new tab) — French public medicines database (BDPM)
  2. 2.Summary of product characteristics of the serotype E botulinum toxin approved in the European Union (EPAR annex I) (opens in a new tab) — European Commission (Union Register of medicinal products)
  3. 3.European public assessment report (EPAR) of the serotype E botulinum toxin (opens in a new tab) — European Commission (Union Register of medicinal products)
  4. 4.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 69497348) (opens in a new tab) — French public medicines database (BDPM)
  5. 5.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 69878363) (opens in a new tab) — French public medicines database (BDPM)
  6. 6.Canadian product monograph of the serotype E botulinum toxin (authorization date: 2026-06-22) (opens in a new tab) — Health Canada
Book an appointmentSOS after an injection